Justin Taylor, Associate Professor at Sylvester Comprehensive Cancer Center, shared a post on X:
“I’m new to the Glioblastoma therapy field, but when the inventor of the Stupp protocol writes an editorial in The Lancet Oncology pleading for progress after 20 years, we need all hands on deck!”
To which Razelle Kurzrock, Founding Director at Michels Rare Cancers Research Laboratories, shared a post on X:
“Good for him.
We use the same therapy as in 2005, when Stupp was published, and everyone is dead at 3 years. And it’s not a nice death either. Another example of “do anything but standard of care”.
Every GBM patient should be offered a clinical trial in first line.”
Other articles featuring Justin Taylor and Razelle Kurzrock on OncoDaily.
